4.7 Article

Redox-Activated Near-Infrared-Responsive Polyoxometalates Used for Photothermal Treatment of Alzheimer's Disease

Journal

ADVANCED HEALTHCARE MATERIALS
Volume 7, Issue 20, Pages -

Publisher

WILEY
DOI: 10.1002/adhm.201800320

Keywords

Alzheimer's disease; amyloid-beta (A beta); near-infrared; phototherapy; polyoxometalates

Funding

  1. National Natural Science Foundation of China [21210002, 21431007, 21533008]
  2. Frontier Science Key Program of CAS [QYZDJ-SSWSLH052]

Ask authors/readers for more resources

Adjustable structure, excellent physiochemical properties, and good biocompatibility render polyoxometalates (POMs) as a suitable drug agent for the treatment of Alzheimer's disease (AD). However, previous works using POMs against AD just focus on the inhibition of amyloid-beta (A beta) monomer aggregation. In consideration that both A beta fibrils and reactive oxygen species (ROS) are closely associated with clinical development of AD symptoms, it would be more effective if POMs can disaggregate A beta fibrils and eliminate ROS as well. Herein, a redox-activated near-infrared (NIR) responsive POMs-based nanoplaform (rPOMs@MSNs@copolymer) is developed with high photothermal effect and antioxidant activity. The rPOMs@MSNs@copolymer can generate local hyperthermia to disaggregate A beta fibrils under NIR laser irradiation because of POMs (rPOMs) with strong NIR absorption. Furthermore, A beta-induced ROS can be scavenged by the antioxidant activity of rPOMs. To the authors' knowledge, there is no report of using rPOMs for NIR photothermal treatment of AD. This work may promote the development of multifunctional inorganic agents for biomedical applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available